Zacks: Innophos Holdings, Inc. (NASDAQ:IPHS) Given $46.00 Consensus Price Target by Analysts

Innophos Holdings, Inc. (NASDAQ:IPHS) has earned a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company.

Analysts have set a twelve-month consensus price objective of $46.00 for the company and are predicting that the company will post $0.63 EPS for the current quarter, according to Zacks. Zacks has also given Innophos an industry rank of 222 out of 256 based on the ratings given to related companies.

A number of equities analysts have weighed in on IPHS shares. Zacks Investment Research lowered Innophos from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. BidaskClub raised Innophos from a “strong sell” rating to a “sell” rating in a research report on Thursday. Finally, TheStreet lowered Innophos from a “b-” rating to a “c+” rating in a research report on Thursday, May 23rd.



NASDAQ:IPHS traded up $0.46 on Friday, reaching $26.49. 58,878 shares of the company’s stock were exchanged, compared to its average volume of 96,994. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.85 and a quick ratio of 1.41. The firm has a market cap of $549.78 million, a price-to-earnings ratio of 11.62 and a beta of 1.43. Innophos has a 52 week low of $22.57 and a 52 week high of $46.65. The stock has a fifty day simple moving average of $27.58 and a 200-day simple moving average of $29.77.

Innophos (NASDAQ:IPHS) last posted its quarterly earnings results on Tuesday, August 6th. The specialty chemicals company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.37 by $0.06. The firm had revenue of $185.04 million for the quarter, compared to the consensus estimate of $196.55 million. Innophos had a net margin of 3.79% and a return on equity of 12.35%. The business’s revenue was down 10.5% compared to the same quarter last year. During the same period last year, the firm posted $0.55 earnings per share. As a group, sell-side analysts predict that Innophos will post 2.27 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 6th. Shareholders of record on Friday, August 23rd will be given a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a yield of 7.25%. The ex-dividend date is Thursday, August 22nd. Innophos’s dividend payout ratio (DPR) is 84.21%.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IPHS. Dimensional Fund Advisors LP raised its stake in Innophos by 3.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,084,227 shares of the specialty chemicals company’s stock valued at $26,596,000 after buying an additional 38,309 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Innophos by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 223,850 shares of the specialty chemicals company’s stock valued at $5,490,000 after buying an additional 12,229 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Innophos by 0.6% in the 4th quarter. Principal Financial Group Inc. now owns 159,254 shares of the specialty chemicals company’s stock valued at $3,907,000 after buying an additional 931 shares during the period. Two Sigma Advisers LP lifted its holdings in shares of Innophos by 1.6% in the 4th quarter. Two Sigma Advisers LP now owns 31,538 shares of the specialty chemicals company’s stock valued at $774,000 after buying an additional 482 shares during the period. Finally, Metropolitan Life Insurance Co. NY lifted its holdings in shares of Innophos by 353.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 6,403 shares of the specialty chemicals company’s stock valued at $157,000 after buying an additional 4,991 shares during the period. 93.26% of the stock is owned by hedge funds and other institutional investors.

Innophos Company Profile

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

Further Reading: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.